Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Amgen

Arcutis Biotherapeutics

Axsome Therapeutics

ImmunityBio

Madrigal Pharmaceuticals

Intellia Therapeutics

Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true.

7 Biotech Stocks to Keep on Your Clinical Radar

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $495.91, indicating a +0.88% shift from the previous trading day.

Here's Why Vertex Pharmaceuticals (VRTX) Gained But Lagged the Market Today

Beam Therapeutics

CRISPR Therapeutics

Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.

3 Gene Editing Stocks Shaping the Future of Medicine

Intuitive Surgical

Exxon Mobil

U.S. M2 money supply has done something that no one has witnessed since the Great Depression. Meanwhile, the benchmark S&P 500 is at one of its priciest valuations in history.

2 Historically Flawless Metrics Suggest the Stock Market Can Plunge: Here Are 3 Stocks I've Sold Ahead of What May Be a Big Move for Wall Street

NeuroOne Medical Technologies Corp

Problems with the central nervous system are the second leading cause of death globally, the World Health Organization determined in 2022. One reason for this situation is that it's extremely difficult to develop effective treatments for these disorders because of the complexity of the CNS, European biotech news website Labiotech reported last year.

The 3 Best Neuroscience Biotech Stocks to Buy Now

Gene editing stocks are often biopharmaceutical companies. At these firms, scientists use technology to change the DNA of organisms such as plants, bacteria and animals.

3 Gene Editing Stocks That Could Grow Your Wealth

ADMA Biologics

Halozyme Therapeutics

Jazz Pharmaceuticals

Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you're investing in companies that are working to treat or heal medical ailments that cause issues for people around the world.

Add These 5 Hot Biotech Stocks In July

ASML Hld

EssilorLuxottica SA

NVIDIA

SAP SE

ASML, SAP, Nvidia, Vertex and EssilorLuxxottica are included in this Analyst Blog.

The Zacks Analyst Blog ASML, SAP, Nvidia, Vertex and EssilorLuxxottica

BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)-- #ADC--A Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum's TPD²® Technology to Develop Novel Degrader-Antibody Conjugates.

Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum's TPD²® Technology to Develop Novel Degrader-Antibody Conjugates

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $490.85, signifying a +0.43% move from its prior day's close.

Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider

HCA Healthcare

These healthcare businesses are booming. Vertex Pharmaceuticals is raking in approvals, cash, and profits.

Got $1,000? 2 Incredible Growth Stocks to Buy and Hold Forever

Vertex's stock has risen 18% since last December, matching the SPY index, bolstered by promising Phase 2 data for VX-548 in diabetic peripheral neuropathy. Vertex is expanding into gene therapies and other rare disease treatments, recently acquiring Alpine Immune Sciences for $4.9 billion to enhance its rare disease pipeline. Q1 2024 earnings exceeded expectations with a 13% revenue increase, primarily from their cystic fibrosis drug, Trikafta/Kaftrio.

Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management

Eli Lilly

Regeneron Pharmaceuticals

Eli Lilly could be headed for a market capitalization above $1 trillion. Regeneron has overcome bumps and shows no signs of slowing down.

3 No-Brainer Stocks to Buy in July

Let's get down to it: why should investors consider pharma stocks? Primarily, it comes down to the permanence of the underlying narrative.

3 Pharma Stocks Already Ushering in the Next Biotech Boom

Vertex has built an empire from cystic fibrosis treatment, generating billions of dollars in annual revenue. The company is set to dominate the market through the late 2030s -- and possibly beyond.

Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).

Investing in biotech can be pretty unpredictable. Biotech stocks are highly volatile, and picking carefully can be the difference between losing all your capital and making unimaginable profits.

The 3 Best Biotech Stocks to Buy in July 2024

Vertex Pharmaceuticals has significantly outpaced the market in the past few decades. The company owes its performance to a well-defined strategy and its innovative abilities.

1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever

Vertex Pharmaceuticals is working on a therapy to treat diabetes. The latest data about that therapy's performance looks solid.

Did Vertex Pharmaceuticals Just Invent the Next Ozempic?

Viking Therapeutics

Amgen is much cheaper than Eli Lilly. Vertex Pharmaceuticals has several major growth drivers.

Forget Eli Lilly: 3 Biotech Stocks to Buy Instead

Schrodinger 

Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9.

3 Top-Rated Gene Editing Stocks Actually Making Money

The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.

Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for investigational once-daily vanzacaftor/tezacaftor/deutivacaftor triple combination therapy (vanza triple) for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) g.

Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis

AbbVie

Pfizer

One of the most important sectors in any country's economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results.

3 Under-the-Radar Biotech Stocks With Blockbuster Potential

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2024 Earnings Call.” The conference call will be webcast live and a link to the webcast c.

Vertex to Announce Second Quarter 2024 Financial Results on August 1

Novo Nordisk

With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, with careful selection of industry leaders.

News for Vertex Pharmaceuticals Stock (VRTX)